To include your compound in the COVID-19 Resource Center, submit it here.
On Oct. 3, Cullinan Oncology LLC (Cambridge, Mass.) raised $150 million in a series A round led by the UBS Oncology Impact Fund
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury